Pierluigi Costanzo, MD, MSc; John G.F. Cleland, MD; Pierpaolo Pellicori, MD; Andrew L. Clark, MD; David Hepburn, MD; Eric S. Kilpatrick, MD; Pasquale Perrone-Filardi, MD, PhD; Jufen Zhang, MSc, PhD; Stephen L. Atkin, MD, PhD
Grant Support: By the National Institute for Health Research, the academic cardiology unit of the Hull York Medical School at the University of Hull, and Imperial College London.
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M14-1551.
Reproducible Research Statement:Study protocol and statistical code: Available from Dr. Costanzo (e-mail, email@example.com). Data set: Not available.
Requests for Single Reprints: Pierluigi Costanzo, MD, MSc, Academic Cardiology Unit, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham HU16 5JQ, United Kingdom; e-mail, firstname.lastname@example.org.
Current Author Addresses: Drs. Costanzo, Pellicori, and Zhang and Prof. Clark: Academic Cardiology Unit, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham HU16 5JQ, United Kingdom.
Prof. Cleland: National Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College, Hill End Road, Harefield, London UB9 6JH, United Kingdom.
Dr. Hepburn: The Michael White Centre for Diabetes and Endocrinology, H.S. Brocklehurst Building, Hull Royal Infirmary, Anlaby Road, Hull HU3 2JZ, United Kingdom.
Prof. Kilpatrick: Department of Clinical Biochemistry, Hull Royal Infirmary, Anlaby Road, Hull HU3 2JZ, United Kingdom.
Prof. Perrone-Filardi: Department of Advanced Biomedical Sciences, Federico II University, Via S. Pansini 5, Naples, Italy 80131.
Prof. Atkin: Weill Cornell Medical College Qatar, Qatar Foundation, Education City, PO Box 24144, Doha, Qatar.
Author Contributions: Conception and design: P. Costanzo, J.G.F. Cleland, S.L. Atkin.
Analysis and interpretation of the data: P. Costanzo, J.G.F. Cleland, A.L. Clark, J. Zhang, S.L. Atkin.
Drafting of the article: P. Costanzo, J.G.F. Cleland, A.L. Clark, S.L. Atkin.
Critical revision of the article for important intellectual content: J.G.F. Cleland, P. Pellicori, A.L. Clark, D. Hepburn, P. Perrone-Filardi, S.L. Atkin.
Final approval of the article: P. Costanzo, J.G.F. Cleland, P. Pellicori, A.L. Clark, D. Hepburn, E.S. Kilpatrick, P. Perrone-Filardi, J. Zhang, S.L. Atkin.
Provision of study materials or patients: P. Costanzo, D. Hepburn, E.S. Kilpatrick, S.L. Atkin.
Statistical expertise: P. Costanzo, J. Zhang.
Obtaining of funding: P. Costanzo, J.G.F. Cleland, S.L. Atkin.
Administrative, technical, or logistic support: P. Costanzo, S.L. Atkin.
Collection and assembly of data: P. Costanzo, D. Hepburn, E.S. Kilpatrick, S.L. Atkin.
Costanzo P, Cleland JG, Pellicori P, Clark AL, Hepburn D, Kilpatrick ES, et al. The Obesity Paradox in Type 2 Diabetes Mellitus: Relationship of Body Mass Index to Prognosis: A Cohort Study. Ann Intern Med. 2015;162:610-618. doi: 10.7326/M14-1551
Download citation file:
Published: Ann Intern Med. 2015;162(9):610-618.
Whether obesity is associated with a better prognosis in patients with type 2 diabetes mellitus is controversial.
To investigate the association between body weight and prognosis in a large cohort of patients with type 2 diabetes followed for a prolonged period.
National Health Service, England.
Patients with diabetes.
The relationship between body mass index (BMI) and prognosis in patients with type 2 diabetes without known cardiovascular disease at baseline was investigated. Information on all-cause mortality and cardiovascular morbidity (such as the acute coronary syndrome, cerebrovascular accidents, and heart failure) was collected. Cox regression survival analysis, corrected for potential modifiers, including cardiovascular risk factors and comorbid conditions (such as cancer, chronic kidney disease, and lung disease), was done.
10 568 patients were followed for a median of 10.6 years (interquartile range, 7.8 to 13.4). Median age was 63 years (interquartile range, 55 to 71), and 54% of patients were men. Overweight or obese patients (BMI >25 kg/m2) had a higher rate of cardiac events (such as the acute coronary syndrome and heart failure) than those of normal weight (BMI, 18.5 to 24.9 kg/m2). However, being overweight (BMI, 25 to 29.9 kg/m2) was associated with a lower mortality risk, whereas obese patients (BMI >30 kg/m2) had a mortality risk similar to that of normal-weight persons. Patients with low body weight had the worst prognosis.
Data about cause of death were not available.
In this cohort, patients with type 2 diabetes who were overweight or obese were more likely to be hospitalized for cardiovascular reasons. Being overweight was associated with a lower mortality risk, but being obese was not.
National Institute for Health Research and University of Hull.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism, Obesity.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only